J Neurol Surg A Cent Eur Neurosurg 2017; 78(04): 407-411
DOI: 10.1055/s-0037-1598052
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Rapid Deterioration of Latent HBV Hepatitis during Cushing Disease and Posttraumatic Stress Disorder after Earthquake

Ryosuke Tashiro
1   Department of Neurosurgery, Kohnan Hospital, Sendai, Miyagi, Japan
Yoshikazu Ogawa
1   Department of Neurosurgery, Kohnan Hospital, Sendai, Miyagi, Japan
Teiji Tominaga
2   Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan
› Author Affiliations
Further Information

Publication History

10 September 2016

14 November 2016

Publication Date:
09 February 2017 (online)


Reactivation of the hepatitis B virus (HBV) is a risk in the 350 million HBV carriers worldwide. HBV reactivation may cause hepatocellular carcinoma, cirrhosis, and fulminant hepatitis, and HBV reactivation accompanied with malignant tumor and/or chemotherapy is a critical problem for patients with chronic HBV infection. Multiple risk factors causing an immunosuppressive state can also induce HBV reactivation.

We present a case of HBV reactivation during an immunosuppressive state caused by Cushing disease and physical and psychological stress after a disaster. A 47-year-old Japanese woman was an inactive HBV carrier until the Great East Japan Earthquake occurred and follow-up was discontinued. One year after the earthquake she had intractable hypertension, and her visual acuity gradually worsened. Head magnetic resonance imaging showed a sellar tumor compressing the optic chiasm, and hepatic dysfunction with HBV reactivation was identified. Endocrinologic examination established the diagnosis as Cushing disease. After normalization of hepatic dysfunction with antiviral therapy, transsphenoidal tumor removal was performed that resulted in subtotal removal except the right cavernous portion. Steroid hormone supplementation was discontinued after 3 days of administration, and gamma knife therapy was performed for the residual tumor. Eighteen months after the operation, adrenocorticotropic hormone and cortisol values returned to normal. The patient has been free from tumor regrowth and HBV reactivation throughout the postoperative course.

Accomplishment of normalization with intrinsic steroid value with minimization of steroid supplementation should be established. Precise operative procedures and careful treatment planning are essential to avoid HBV reactivation in patients with this threatening condition.

  • References

  • 1 Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 2015; 62 (1, Suppl) S76-S86
  • 2 Lozano R, Naghavi M, Foreman K. , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2095-2128
  • 3 Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350 (11) 1118-1129
  • 4 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14 (03) 381-396
  • 5 Tong MJ, Trieu J. Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis 2013; 14 (06) 311-317
  • 6 Bae JH, Sohn JH, Lee HS. , et al. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 2012; 18 (02) 225-228
  • 7 Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002; 9 (06) 424-428
  • 8 Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49 (5, Suppl): S156-S165
  • 9 Hui CK, Cheung WW, Zhang HY. , et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131 (01) 59-68
  • 10 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90 (01) 13-23
  • 11 López-Serrano P, de la Fuente Briongos E, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7 (03) 539-547
  • 12 Mori N, Suzuki F, Kawamura Y. , et al. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 2012; 47 (09) 1022-1029
  • 13 Pei SN, Chen CH, Lee CM. , et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89 (03) 255-262
  • 14 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148 (01) 221-244.e3
  • 15 Fattovich G, Brollo L, Alberti A. , et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990; 10 (03) 141-146
  • 16 Kamitsukasa H, Iri M, Tanaka A. , et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol 2015; 87 (04) 589-600
  • 17 Perrillo RP, Campbell CR, Sanders GE, Regenstein FG, Bodicky CJ. Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med 1984; 100 (01) 43-46
  • 18 Sarin SK, Kumar M, Shrivastava S, Sinha S, Pati NT. Influence of chronic HBV infection on pregnancy: a human model of maternofetal virus host interactions. Gastroenterology 2011; 141 (04) 1522-1525
  • 19 Smith PJ, Suri D. Adrenalectomy to treat reactivated chronic hepatitis B infection in a patient with a steroid-secreting adrenal tumour. BMJ Case Rep 2011; 2011 DOI: 10.1136/bcr.11.2010.3508.
  • 20 Tsou PL, Lee HS, Jeng YM, Huang TS. Submassive liver necrosis in a hepatitis B carrier with Cushing's syndrome. J Formos Med Assoc 2002; 101 (02) 156-158
  • 21 Loomba R, Rowley A, Wesley R. , et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148 (07) 519-528
  • 22 Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28 (01) 28-38
  • 23 Cheng AL, Hsiung CA, Su IJ. , et al; Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37 (06) 1320-1328
  • 24 Fukushima N, Mizuta T, Tanaka M. , et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20 (12) 2013-2017
  • 25 Fatemi N, Dusick JR, Mattozo C. , et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 2008; 63 (04) 709-718 ; discussion 718–719
  • 26 Xu Z, Lee Vance M, Schlesinger D, Sheehan JP. Hypopituitarism after stereotactic radiosurgery for pituitary adenomas. Neurosurgery 2013; 72 (04) 630-637 , 636–637
  • 27 Masarone M, De Renzo A, La Mura V. , et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014; 14: 31 . doi: 10.1186/1471-230X-14-31